DrugPatentWatch Database Preview
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE Drug Profile
» See Plans and Pricing
When do Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide patents expire, and when can generic versions of Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide launch?
Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide is a drug marketed by Par Pharm Inc, Teva Pharms Usa, and Torrent. and is included in three NDAs.
The generic ingredient in OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE is amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil. There are fifty drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil profile page.
Summary for OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Suppliers / Packagers: | 4 |
| Clinical Trials: | 8 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE? | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE excipients list |
| DailyMed Link: | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daiichi Sankyo Korea Co., Ltd. | Phase 3 |
| Torrent Pharmaceuticals Limited | Phase 1 |
| Integrium | Phase 4 |
See all OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE clinical trials
Pharmacology for OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
| Drug Class | Angiotensin 2 Receptor Blocker Dihydropyridine Calcium Channel Blocker Thiazide Diuretic |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists |
| Physiological Effect | Increased Diuresis |
